Vertex Soars On Clinical Data And Boosts Biotech Stocks
March 29, 2017 at 22:00 PM EDT
Vertex Pharmaceuticals soared over 20% to $108 on released Phase 3 clinical data for their cystic fibrosis drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.